Sahay S, Lundh A, Sirole R, McCullumsmith R, ODonovan S
Int J Mol Sci. 2025; 26(5).
PMID: 40076453
PMC: 11898938.
DOI: 10.3390/ijms26051826.
Shi H, Ditter I, Oken A, Mansoor S
Sci Adv. 2025; 11(3):eadr3315.
PMID: 39823330
PMC: 11740937.
DOI: 10.1126/sciadv.adr3315.
Leiva-Salcedo E, Riquelme D, Huidobro-Toro J, Coddou C
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770432
PMC: 11678522.
DOI: 10.3390/ph17121590.
Oken A, Ditter I, Lisi N, Krishnamurthy I, Godsey M, Mansoor S
Sci Adv. 2024; 10(40):eado5084.
PMID: 39365862
PMC: 11451537.
DOI: 10.1126/sciadv.ado5084.
Bayram Z, Akcabag E, Ozbey G, Nacitarhan C, Ozdem S, Turkay C
Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):2027-2037.
PMID: 39225832
DOI: 10.1007/s00210-024-03411-1.
Microglia in Neuropathic Pain.
Inoue K
Adv Neurobiol. 2024; 37:399-403.
PMID: 39207704
DOI: 10.1007/978-3-031-55529-9_22.
High-affinity agonism at the P2X receptor is mediated by three residues outside the orthosteric pocket.
Oken A, Lisi N, Krishnamurthy I, McCarthy A, Godsey M, Glasfeld A
Nat Commun. 2024; 15(1):6662.
PMID: 39107314
PMC: 11303814.
DOI: 10.1038/s41467-024-50771-6.
The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy.
Thakku Sivakumar D, Jain K, Alfehaid N, Wang Y, Teng X, Fischer W
Int J Mol Sci. 2024; 25(13).
PMID: 39000004
PMC: 11241490.
DOI: 10.3390/ijms25136894.
Nocturia and obstructive sleep apnoea.
Vrooman O, van Kerrebroeck P, van Balken M, van Koeveringe G, Rahnamai M
Nat Rev Urol. 2024; 21(12):735-753.
PMID: 38783115
DOI: 10.1038/s41585-024-00887-7.
Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists.
Sheng D, Yue C, Jin F, Wang Y, Ichikawa M, Yu Y
Elife. 2024; 12.
PMID: 38578670
PMC: 10997329.
DOI: 10.7554/eLife.92829.
Extracellular Purine Metabolism-Potential Target in Multiple Sclerosis.
Laketa D, Lavrnja I
Mol Neurobiol. 2024; 61(10):8361-8386.
PMID: 38499905
DOI: 10.1007/s12035-024-04104-9.
ATP homeostasis and signaling in plants.
Xiao J, Zhou Y, Xie Y, Li T, Su X, He J
Plant Commun. 2024; 5(4):100834.
PMID: 38327057
PMC: 11009363.
DOI: 10.1016/j.xplc.2024.100834.
Integrating UHPLC-MS/MS quantitative analysis and exogenous purine supplementation to elucidate the antidepressant mechanism of Chaigui granules by regulating purine metabolism.
Chen J, Li T, Huang D, Gong W, Tian J, Gao X
J Pharm Anal. 2024; 13(12):1562-1576.
PMID: 38223448
PMC: 10785246.
DOI: 10.1016/j.jpha.2023.08.008.
Purinergic signaling in the battlefield of viral infections.
Carvalho-Barbosa N, Zeidler J, Savio L, Coutinho-Silva R
Purinergic Signal. 2023; .
PMID: 38038801
DOI: 10.1007/s11302-023-09981-8.
Purinergic system in cancer stem cells.
Nunez-Rios J, Ulrich H, Diaz-Munoz M, Lameu C, Vazquez-Cuevas F
Purinergic Signal. 2023; 21(1):23-38.
PMID: 37966629
PMC: 11904000.
DOI: 10.1007/s11302-023-09976-5.
Involvement of microglial P2X7 receptor in pain modulation.
Zhang J, Gao L, Zhang Y, Wang H, Sun S, Wu L
CNS Neurosci Ther. 2023; 30(1):e14496.
PMID: 37950524
PMC: 10805404.
DOI: 10.1111/cns.14496.
ATP functions as a primary alarmin in allergen-induced type 2 immunity.
OGrady S, Kita H
Am J Physiol Cell Physiol. 2023; 325(5):C1369-C1386.
PMID: 37842751
PMC: 10861152.
DOI: 10.1152/ajpcell.00370.2023.
Structural insights into the allosteric inhibition of P2X4 receptors.
Shen C, Zhang Y, Cui W, Zhao Y, Sheng D, Teng X
Nat Commun. 2023; 14(1):6437.
PMID: 37833294
PMC: 10575874.
DOI: 10.1038/s41467-023-42164-y.
Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence.
Daniels S, Boison D
Neuropharmacology. 2023; 241:109756.
PMID: 37820933
PMC: 10841508.
DOI: 10.1016/j.neuropharm.2023.109756.
Purine and purinergic receptors in health and disease.
Ai Y, Wang H, Liu L, Qi Y, Tang S, Tang J
MedComm (2020). 2023; 4(5):e359.
PMID: 37692109
PMC: 10484181.
DOI: 10.1002/mco2.359.
